132 related articles for article (PubMed ID: 38306232)
1. Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
Veneziani AC; Sneha S; Oza AM
Clin Cancer Res; 2024 Apr; 30(8):1434-1437. PubMed ID: 38306232
[TBL] [Abstract][Full Text] [Related]
2. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract][Full Text] [Related]
3. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
Fauci JM; Straughn JM; Ferrone S; Buchsbaum DJ
Gynecol Oncol; 2012 Nov; 127(2):420-5. PubMed ID: 22910694
[TBL] [Abstract][Full Text] [Related]
4. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
Kryczek I; Zou L; Rodriguez P; Zhu G; Wei S; Mottram P; Brumlik M; Cheng P; Curiel T; Myers L; Lackner A; Alvarez X; Ochoa A; Chen L; Zou W
J Exp Med; 2006 Apr; 203(4):871-81. PubMed ID: 16606666
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
MacGregor HL; Ohashi PS
Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
[TBL] [Abstract][Full Text] [Related]
6. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
7. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
8. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
[TBL] [Abstract][Full Text] [Related]
9. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
[TBL] [Abstract][Full Text] [Related]
10. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
11. [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
Zhang LL; Shao SL; Wu Y
Chin J Cancer; 2010 Jan; 29(1):25-9. PubMed ID: 20038306
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
13. RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
Zheng C; Yang R
J BUON; 2019; 24(2):715-719. PubMed ID: 31128028
[TBL] [Abstract][Full Text] [Related]
14. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
15. B7-H4 expression promotes tumorigenesis in ovarian cancer.
Cheng L; Jiang J; Gao R; Wei S; Nan F; Li S; Kong B
Int J Gynecol Cancer; 2009 Dec; 19(9):1481-6. PubMed ID: 19955922
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
Toader D; Fessler SP; Collins SD; Conlon PR; Bollu R; Catcott KC; Chin CN; Dirksen A; Du B; Duvall JR; Higgins S; Kozytska MV; Bellovoda K; Faircloth C; Lee D; Li F; Qin L; Routhier C; Shaw P; Stevenson CA; Wang J; Wongthida P; Ter-Ovanesyan E; Ditty E; Bradley SP; Xu L; Yin M; Yurkovetskiy AV; Mosher R; Damelin M; Lowinger TB
Mol Cancer Ther; 2023 Sep; 22(9):999-1012. PubMed ID: 37294948
[TBL] [Abstract][Full Text] [Related]
17. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
18. New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.
Pommier Y; Thomas A
Clin Cancer Res; 2023 Mar; 29(6):991-993. PubMed ID: 36637483
[TBL] [Abstract][Full Text] [Related]
19. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Kinneer K; Wortmann P; Cooper ZA; Dickinson NJ; Masterson L; Cailleau T; Hutchinson I; Vijayakrishnan B; McFarlane M; Ball K; Davies M; Lewis A; Huang Y; Rosenbaum AI; Yuan J; Chesebrough J; Anderton J; Monks N; Novick S; Wang J; Dimasi N; Christie RJ; Sabol D; Tosto FA; Wallez Y; Leo E; Albertella MR; Staniszewska AD; Tice DA; Howard PW; Luheshi N; Sapra P
Clin Cancer Res; 2023 Mar; 29(6):1086-1101. PubMed ID: 36355054
[TBL] [Abstract][Full Text] [Related]
20. B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer.
Pagnotti GM; Atkinson RM; Romeiser J; Akalin A; Korman MB; Shroyer KR
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):515-522. PubMed ID: 29189263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
